Primary sclerosing cholangitis and the microbiota: Current knowledge and perspectives on etiopathogenesis and emerging therapies

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 8, 2014, Pages 901-908

  Tabibian, James H ^a   O'Hara, Steven P ^a   Lindor, Keith D ^b  

^a MAYO CLINIC   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Cholestatic; Etiopathogenesis; Metabolites

Indexed keywords

AZITHROMYCIN; METRONIDAZOLE; MINOCYCLINE; SALAZOSULFAPYRIDINE; TETRACYCLINE; URSODEOXYCHOLIC ACID; VANCOMYCIN;

DEATH; DISEASE ASSOCIATION; DISEASE COURSE; ENTEROHEPATIC CIRCULATION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLITE; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; COLON TUMOR; COMPLICATION; EVIDENCE BASED MEDICINE; LIVER TUMOR; MICROBIOLOGY; MICROFLORA; PATHOLOGY; PROGNOSIS; SCLEROSING CHOLANGITIS;

CHOLANGITIS, SCLEROSING; COLONIC NEOPLASMS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICROBIOTA; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84904414417     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.913189     Document Type: Review

References (70)

1. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: A review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol 2013;7:103-14.
2. Gupta A, Bowlus CL. Primary sclerosing cholangitis: Etiopathogenesis and clinical management. Front Biosci 2012;4: 1683-705.
3. Tabibian JH, Lindor KD. Challenges of cholangiocarcinoma detection in patients with primary sclerosing cholangitis. J Anal Oncol 2012;1:50-5.
4. Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008;48:S38-57.
5. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis 2010;42:390-400.
6. Jussila A, Virta LJ, Pukkala E, Farkkila MA. Malignancies in patientswithinflammatoryboweldisease:anationwideregister study in Finland. Scand J Gastroenterol 2013;48:1405-13.
7. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78.
8. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-40.
9. Landaverde C, Ng V, Sato A, Tabibian J, Durazo F, Busuttil R. De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis. Ann Hepatol 2009;8:379-83.
10. Beuers U, Boberg KM, Chapman RW, Chazouillères O, Invernizzi P, Jones DE, et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
11. Brandsaeter B, Friman S, Broome U, Isoniemi H, Olausson M, Backman L, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003;38:1176-83. (Pubitemid 37518603)
12. Ali JM, Bonomo L, Brais R, Griffiths WJ, Lomas DJ, Huguet EL, et al. Outcomes and diagnostic challenges posed by incidental cholangiocarcinoma after liver transplantation. Transplantation 2011;91:1392-7.
13. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003;9:727-32. (Pubitemid 36874461)
14. Welcker K, Martin A, Kolle P, Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004;9:456-60.
15. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, et al. Genetic basis for increased intestinal permeability in families with Crohns disease: role of CARD15 3020insC mutation? Gut 2006;55:342-7. (Pubitemid 43268271)
16. OHara SP, Tabibian JH, Splinter PL, Larusso NF. The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol 2013;58:575-82.
17. OMahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006;26:3-21. (Pubitemid 43320723)
18. Bjornsson E, Cederborg A, Akvist A, Simren M, Stotzer PO, Bjarnason I. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2005;40:1090-4. (Pubitemid 41291359)
19. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis -A pilot study. Aliment Pharmacol Ther 2013;37:604-12.
20. Mueller T, Beutler C, Pico AH, Shibolet O, Pratt DS, Pascher A, et al. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int 2011;31:1574-88.
21. Tabibian JH MA, Masyuk TV, LaRusso NF. Cholangiocyte physiology. Compr Physiol 2013;3:541-65.
22. OHara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, LaRusso NF. Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J Biol Chem 2011;286:30352-60.
23. Yokoyama T, Komori A, Nakamura M, Takii Y, Kamihira T, Shimoda S, et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int 2006;26:467-76.
24. Harada K, Nakanuma Y. Biliary innate immunity and cholangiopathy. Hepatol Res 2007;37:S430-7. (Pubitemid 47570656)
25. Osnes T, Sandstad O, Skar V, Osnes M. Lipopolysaccharides and beta-glucuronidase activity in choledochal bile in relation to choledocholithiasis. Digestion 1997;58:437-43. (Pubitemid 27445611)
26. Chen XM, OHara SP, LaRusso NF. The immunobiology of cholangiocytes. Immunol Cell Biol 2008;86:497-505.
27. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991;13:766-72.
28. Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992;90:1313-22.
29. Lichtman SN, Wang J, Clark RL. A microcholangiographic study of liver disease models in rats. Acad Radiol 1995;2: 515-21.
30. Yamada S, Ishii M, Liang LS, Yamamoto T, Toyota T. Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats. J Gastroenterol 1994;29: 631-6. (Pubitemid 24308414)
31. Haruta I, Kikuchi K, Hashimoto E, Nakamura M, Miyakawa H, Hirota K, et al. Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation. Lab Invest 2010;90: 577-88.
32. Karrar A, Broome U, Sodergren T, Jaksch M, Bergquist A, Bjornstedt M, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007;132:1504-14. (Pubitemid 46627575)
33. Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? -"its hard to be a PSC model!". Clin Res Hepatol Gastroenterol 2011;35:792-804.
34. Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006; 18:69-74. (Pubitemid 43004884)
35. Hiramatsu K, Harada K, Tsuneyama K, Sasaki M, Fujita S, Hashimoto T, et al. Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. J Hepatol 2000; 33:9-18. (Pubitemid 30418928)
36. Olsson R, Bjornsson E, Backman L, Friman S, Hockerstedt K, Kaijser B, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: A study of explanted livers. J Hepatol 1998;28:426-32. (Pubitemid 28133546)
37. Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998;29:409-16. (Pubitemid 28396657)
38. Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012;57:366-75.
39. Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670-5.
40. McGovern DP, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, et al. Fucosyltransferase 2 (FUT2) nonsecretor status is associated with Crohns disease. Hum Mol Genet 2010;19:3468-76.
41. Eksteen B, Mora JR, Haughton EL, Henderson NC, Lee-Turner L, Villablanca EJ, et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 2009; 137:320-9.
42. Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004; 200:1511-17. (Pubitemid 39657298)
43. Borchers AT, Shimoda S, Bowlus C, Keen CL, Gershwin ME. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol 2009;31:309-22.
44. Tabibian JH, OHara SP, Splinter PL, Trussoni CE, Larusso NF. Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 2014; Epub ahead of print.
45. Jeyapalan JC, Sedivy JM. Cellular senescence and organismal aging. Mech Ageing Dev 2008;129:467-74.
46. Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, et al. Fat tissue, aging, and cellular senescence. Aging Cell 2010;9:667-84.
47. Campisi J, dAdda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-40. (Pubitemid 47312822)
48. Burton DG. Cellular senescence, ageing and disease. Age (Omaha) 2009;31:1-9.
49. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 2013;123:966-72.
50. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6: 2853-68.
51. Trougakos IP, Saridaki A, Panayotou G, Gonos ES. Identification of differentially expressed proteins in senescent human embryonic fibroblasts. Mech Ageing Dev 2006; 127:88-92. (Pubitemid 41713520)
52. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133:1019-31. (Pubitemid 351787746)
53. Acosta JC, OLoghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008;133:1006-18. (Pubitemid 351795610)
54. Tabibian JH, Macura SI, OHara SP, Fidler JL, Glockner JF, Takahashi N, et al. Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, livemouse cholangiography. Lab Invest 2013;93:733-43.
55. Melum E, Franke A, Schramm C, Weismuller TJ, Gotthardt DN, Offner FA, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011;43:17-19.
56. Rankin JG, Boden RW, Goulston SJ, Morrow W. The liver in ulcerative colitis; treatment of pericholangitis with tetracycline. Lancet 1959;2:1110-12.
57. Elfaki DA, Lindor KD. Antibiotics for the treatment of primary sclerosing cholangitis. Am J Ther 2011;18:261-5.
58. Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. Hepatology 2004; 40:1379-86. (Pubitemid 39657012)
59. Silveira MG, Torok NJ, Gossard AA, Keach JC, Jorgensen RA, Petz JL, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009;104:83-8.
60. Mistilis SP, Skyring AP, Goulston SJ. Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis. Australas Ann Med 1965;14:286-94.
61. Kozaiwa K, Tajiri H, Sawada A, Tada K, Etani Y, Miki K, et al. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J Gastroenterol Hepatol 1998;13:825-9. (Pubitemid 28374900)
62. Cox KL, Cox KM. Oral vancomycin: Treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998;27:580-3. (Pubitemid 28492259)
63. Broccoletti T CE, Spaziano M, Capuano G, Petrone E, Mandato C, Migliaro F, et al. Refractory primary sclerosing cholangitis becoming responsive after sulphasalazine treatment of an underlying silent colitis. Ital J Pediatr 2002;28:515-17. (Pubitemid 36383057)
64. Tada S, Ebinuma H, Saito H, Hibi T. Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J Gastroenterol 2006;41:388-9. (Pubitemid 43834384)
65. Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: A case report and serendipitous observation. Int J Immunopathol Pharmacol 2007;20:847-9.
66. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: An immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008;47:61-7.
67. Mathew KK. Metronidazole in primary cholangitis. J Indian Med Assoc 1983;80:31; 33.
68. Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transpl 2013;2013:314292.
69. Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: A randomized placebocontrolled crossover pilot study. Eur J Gastroenterol Hepatol 2008;20:688-92.
70. Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013;33: 397-406.